CVS Pharmacy vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Largest US pharmacy chain with ~9,000 locations; expanding pharmacy-only format in 2026; parent CVS Health also operates Aetna (health insurance) and Caremark (PBM), creating a vertically integrated healthcare mega-platform from pharmacy to insura...
About
CVS Pharmacy is the largest pharmacy chain in the United States, operating approximately 9,000 retail pharmacy locations nationwide. Founded in 1963 and headquartered in Woonsocket, Rhode Island, CVS has grown from a regional drugstore chain into a healthcare mega-platform through decades of acquisitions and vertical integration. The retail pharmacy business — dispensing prescriptions, selling health and wellness products, and providing immunizations and clinical services — is the customer-facing foundation of a much larger healthcare enterprise that includes pharmacy benefit management and health insurance.\n\nCVS Pharmacy is the consumer brand within the broader CVS Health corporation, which also operates Caremark (one of the largest pharmacy benefit managers in the US, processing hundreds of millions of prescriptions annually) and Aetna (a major health insurer with tens of millions of members). This integration of retail pharmacy, PBM, and health insurance makes CVS Health one of the most vertically integrated healthcare companies in the world, with levers spanning drug dispensing, formulary management, and member health management across the full care continuum. CVS has also expanded into primary care through its MinuteClinics and the acquisition of Oak Street Health.\n\nIn 2026, CVS Pharmacy is actively expanding its pharmacy-only format — smaller footprint locations focused exclusively on prescription fulfillment and clinical pharmacy services, rather than the traditional front-end retail merchandise mix. This format evolution reflects a strategic pivot toward healthcare services as retail foot traffic shifts to e-commerce. CVS Health reported approximately $372B in total revenue, reflecting its scale across all business segments. The company faces ongoing margin pressure from drug pricing dynamics and PBM reform discussions, but its integrated model and massive national footprint make it a structurally important player in US healthcare delivery.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.